Sweden Archives

Jennie Ekbeck, CEO Umeå Biotech Incubator

News and Trends 29 Sep 2022

Umeå Biotech Incubator launches international coaching program

The Umeå Biotech Incubator (UBI) in Sweden specializes in developing life science business ideas. Now it is launching an international incubator program. “If you strive to be one of the world’s best incubators you must have the whole world as your marketplace,” said Jennie Ekbeck, CEO of Umeå Biotech Incubator. Umeå Biotech Incubator was founded […]

September 29, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 26 Sep 2022

Mucocort signs deal for pain-relieving mouth ulcer treatment

Mucocort AB is a Swedish company that has developed a unique self-absorbing pain relief patch for people suffering from recurrent mouth ulcers – aphthous stomatitis. The company has signed a production agreement with medical technology company Aurena Laboratories AB, which also becomes a stakeholder in Mucocort. Aphthous stomatitis is a common disorder. Sixty percent of […]

September 26, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 23 Sep 2022

Knockback for drug to treat patients with relapsed or refractory multiple myeloma

A Swedish biotech company says it believes its treatment could be the ‘canary in the coalmine’ despite a knockback. The Oncologic Drugs Advisory Committee (ODAC) has said it does not consider the treatment for patients with relapsed or refractory multiple myeloma (RRMM) favorable in a benefit-risk profile. Oncopeptides AB has been trialing Pepaxto in the […]

September 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Sep 2022

Beyond Biotech podcast 15: Cullinan Oncology, Pleco Therapeutics, TikoMed

This week’s podcast has three guests. In honor of World Cancer Research Day on September 24, we have an overview of cancer research with Nadim Ahmed, CEO of Cullinan Oncology; a chat with Ivo Timmermans, CEO of Pleco Therapeutics; and talk with Anders Kristensson, CEO of TikoMed. We also have our weekly chat with global […]

September 23, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 19 Sep 2022

Cyxone receives approval for phase 2b rheumatoid arthritis study

Swedish biotech company Cyxone has received approval from the Medical Product Agency (Office for Registration of Medicinal Products, Medical devices and Biocides) and the Central Ethics Committee in Poland to start a clinical phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA). “The approval is […]

September 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Sep 2022

Beyond Biotech podcast 14: Nordic Life Science NLS Days 2022

This week’s podcast is dedicated to Nordic Life Science Days, otherwise known as NLS Days. This year’s version is an in-person event from September 28-29, at the Malmömässan in Malmö, Sweden. In our preview of NLS Days, which features sessions and fireside chats, company presentations, an exhibition, and one-on-one partnering meetings, we have interviews with […]

September 16, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Sep 2022

Omnio receives funding for wound treatment

Swedish company Omnio AB has shown plasminogen is a pro-inflammatory regulator of inflammation that can be used to treat chronic wounds with dysfunctional inflammation. The company, a spin off from Umeå University, said the drug could mean a global treatment revolution for wounds that never heal. Non-healing chronic wounds are a major global health problem […]

September 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

Oncopeptides receives grant for NK-cell engager project in multiple myeloma

Oncopeptides AB has received a SEK 5 million ($465,000) research grant from Sweden’s Innovation Agency. The Swedish biotech company, which focuses on R&D of therapies for difficult-to-treat hematological diseases, will use the funds to develop a preclinical proof of concept (PoC) for a novel synthetic small polypeptide for the treatment of multiple myeloma. The compound […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

In Depth 7 Sep 2022

The biggest private biotech investments in August 2022

The healthcare-focused companies Orna Therapeutics, F2G and Sironax bagged the biggest biotech investments in August 2022, with mRNA vaccines, genomics and fermentation technology attracting big funding rounds. As many took a well-deserved vacation in the month of August 2022, the world of biotech remained busy with fundraising. Sit back and browse our lists of the […]

September 7, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 7 Sep 2022

Alzinova announces new positive safety review for Alzheimer’s study

Alzinova AB says a second external safety review has been carried out of its clinical phase 1b study. This resulted in a positive assessment to continue the study as planned. Behind the review is an independent expert group, Data and Safety Monitoring Board (DSMB), which continuously reviews the study. Based on the patients included in […]

September 7, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 7 Sep 2022

TikoMed drug inhibits infection of human cells by dengue, zika and yellow fever viruses

TikoMed has announced the inclusion in bioRxiv of an in vitro study examining the ability of the company’s lead drug candidate ILB to inhibit infection of human cells by four serotypes of dengue virus (DENV1-4), two strains of zika virus (African and Asian) and yellow fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 6 Sep 2022

IRLAB’s partner Ipsen starts mesdopetam clinical studies

IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, says its partner, Ipsen, has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan. These are standard clinical pharmacokinetic studies that will run in parallel to the phase IIb study with […]

September 6, 2022 - 3 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Sweden

Umeå Biotech Incubator launches international coaching program

Mucocort signs deal for pain-relieving mouth ulcer treatment

Knockback for drug to treat patients with relapsed or refractory multiple myeloma

Beyond Biotech podcast 15: Cullinan Oncology, Pleco Therapeutics, TikoMed

Cyxone receives approval for phase 2b rheumatoid arthritis study

Beyond Biotech podcast 14: Nordic Life Science NLS Days 2022

Omnio receives funding for wound treatment

Oncopeptides receives grant for NK-cell engager project in multiple myeloma

The biggest private biotech investments in August 2022

Alzinova announces new positive safety review for Alzheimer’s study

TikoMed drug inhibits infection of human cells by dengue, zika and yellow fever viruses

IRLAB’s partner Ipsen starts mesdopetam clinical studies

Subscribe to our newsletter to get the latest biotech news!